Abstract
This review focuses on the current findings regarding interaction between amyloid β peptide (Aβ) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimers disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Aβ on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Aβ-RAGE interaction exaggerates neuronal stress, accumulation of Aβ, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Aβ-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.
Keywords: amyloid precursor protein, AD brains, neurofibrillary tangles, endothelin 1, blood-brain barrier
Current Molecular Medicine
Title: RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Volume: 7 Issue: 8
Author(s): Shi Du Yan, Xi Chen, Douglas G. Walker, Ann Marie Schmidt, Ottavio Arancio and Lih-Fen Lue
Affiliation:
Keywords: amyloid precursor protein, AD brains, neurofibrillary tangles, endothelin 1, blood-brain barrier
Abstract: This review focuses on the current findings regarding interaction between amyloid β peptide (Aβ) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimers disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Aβ on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Aβ-RAGE interaction exaggerates neuronal stress, accumulation of Aβ, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Aβ-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.
Export Options
About this article
Cite this article as:
Yan Du Shi, Chen Xi, Walker G. Douglas, Schmidt Marie Ann, Arancio Ottavio and Lue Lih-Fen, RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease, Current Molecular Medicine 2007; 7 (8) . https://dx.doi.org/10.2174/156652407783220741
DOI https://dx.doi.org/10.2174/156652407783220741 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Targeting PPAR Isoforms Following CNS Injury
Current Drug Targets Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets Other Proteins Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science In Silico Identification of Potential Dynamin-Related Protein 1 Antagonists: Implications for Diseases Involving Mitochondrial Dysfunction
Combinatorial Chemistry & High Throughput Screening The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration
Current Molecular Medicine Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Quantitative Ultrasound of Orofacial Muscles in Infants from 6 Months to 5 Years: Collecting Normal Values
Current Medical Imaging Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Aging and Proteins: What Does Proteostasis Have to Do with Age?
Current Molecular Medicine Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Amyloid Deposition and Inflammation in APPswe/PS1dE9 Mouse Model of Alzheimers Disease
Current Alzheimer Research Regulation of Apo E Expression by the Nuclear Receptors- LXRs and FXR
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents GABAA Receptor Specific Pyrazolopyrimidines as Potential Imaging Agents: In Vivo Characteristics of a New 18F-labelled Indiplon Derivative
Current Radiopharmaceuticals Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets